The Cardiovascular Continuum describes a sequence of events from cardiovascular risk factors to end‐stage heart disease. It includes conventional pathologies affecting cardiovascular functions such as hypertension, atherosclerosis or thrombosis and was traditionally considered from the metabolic point of view. This Cardiovascular Continuum, originally described by Dzau and Braunwald, was extended by O'Rourke to consider also the crucial role played by degradation of elastic fibers, occurring during aging, in the appearance of vascular stiffness, another deleterious risk factor of the continuum. However, the involvement of the elastin degradation products, named elastin‐derived peptides, to the Cardiovascular Continuum progression has not been considered before. Data from our laboratory and others clearly showed that these bioactive peptides are central regulators of this continuum, thereby amplifying appearance and evolution of cardiovascular risk factors such as diabetes or hypertension, of vascular alterations such as atherothrombosis and calcification, but also nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. The Elastin Receptor Complex has been shown to be a crucial actor in these processes. We propose here the participation of these elastin‐derived peptides and of the Elastin Receptor Complex in these events, and introduce a revisited Cardiovascular Continuum based on their involvement, for which elastin‐based pharmacological strategies could have a strong impact in the future.
TAX2 peptide is a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its anti-angiogenic activities and showed anti-cancer efficacy in numerous preclinical models. Here, we aimed at providing an extensive molecular characterization of TAX2 mode of action, while evaluating its potential in ovarian cancer therapy. Multidisciplinary approaches were used to qualify a TAX2 drug candidate in terms of stability, solubility and potency. Then, efficacy studies, together with benchmark experiments, were performed in relevant mouse models of ovarian carcinoma. TAX2 peptide appears to be stable and soluble in clinically relevant solvents, while displaying a favorable safety profile. Moreover, clinical data mining allowed for the identification of TSP-1 as a relevant pharmacological target in ovarian cancer. In mice, TAX2 therapy inhibits ovarian tumor growth and metastatic dissemination, while activating anti-cancer adaptive immunity. Interestingly, TAX2 also synergizes when administered in combination with anti-PD-1 immune checkpoint inhibitiors. Altogether, our data expose TAX2 as an optimized candidate with advanced preclinical characterization. Using relevant syngeneic ovarian carcinoma models, we highlighted TAX2’s ability to convert poorly immunogenic tumors into ones displaying effective anti-tumor T-cell immunity.
1 January 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Objective: TSP-1 (thrombospondin 1) is one of the most expressed proteins in platelet α-granules and plays an important role in the regulation of hemostasis and thrombosis. Interaction of released TSP-1 with CD47 membrane receptor has been shown to regulate major events leading to thrombus formation, such as, platelet adhesion to vascular endothelium, nitric oxide/cGMP (cyclic guanosine monophosphate) signaling, platelet activation as well as aggregation. Therefore, targeting TSP-1:CD47 axis may represent a promising antithrombotic strategy. Approach and Results: A CD47-derived cyclic peptide was engineered, namely TAX2, that targets TSP-1 and selectively prevents TSP-1:CD47 interaction. Here, we demonstrate for the first time that TAX2 peptide strongly decreases platelet aggregation and interaction with collagen under arterial shear conditions. TAX2 also delays time for complete thrombotic occlusion in 2 mouse models of arterial thrombosis following chemical injury, while Thbs1−/− mice recapitulate TAX2 effects. Importantly, TAX2 administration is not associated with increased bleeding risk or modification of hematologic parameters. Conclusions: Overall, this study sheds light on the major contribution of TSP-1:CD47 interaction in platelet activation and thrombus formation while putting forward TAX2 as an innovative antithrombotic agent with high added-value.
La TSP-1 est l’une des protéines les plus exprimées dans les granules α des plaquettes et joue un rôle important dans la régulation de la thrombose. L’interaction de la TSP-1 sécrétée avec le récepteur membranaire CD47 régule des événements majeurs conduisant à la formation du thrombus, tels que l’adhérence à l’endothélium vasculaire, l’activation, la signalisation ainsi que l’agrégation plaquettaire.Dans cette thèse, nous démontrons qu’un peptide cyclique dérivé de CD47, nommé TAX2, antagoniste orthostérique de l’interaction TSP-1:CD47, diminue significativement l’agrégation plaquettaire induite par différents agonistes dans des échantillons biologiques humains de complexité croissante. TAX2 inhibe également l’interaction des plaquettes avec le collagène dans des conditions de cisaillement artériel. In vivo, TAX2 retarde le temps d’occlusion thrombotique totale dans deux modèles murins de thrombose artérielle chimio-induite, et récapitule les effets anti-thrombotiques observés chez les souris Thbs1−/−. De manière importante, l’administration aiguë ou chronique de TAX2 est sûre et n’est pas associée à un risque accru de saignement ni à une modification des paramètres de la coagulation.Les plaquettes jouent, par ailleurs, un rôle primordial lors de l’établissement des foyers métastatiques d’origine hématogène qui nécessitent l’arrêt, la fixation et l’extravasation des cellules tumorales. Dans la lignée des découvertes récentes démontrant l’efficacité des médicaments anti-thrombotiques actuels en tant qu’agents anti-tumoraux, nos résultats démontrent la capacité de TAX2 à diminuer la taille des hétéro-agrégats de plaquettes et de cellules cancéreuses de mélanome B16F10, ainsi que le nombre de cellules cancéreuses par agrégats. TAX2 réduit également de manière significative la potentialisation par les plaquettes des capacités d’adhérence, de migration, de migration trans-endothéliale et d’invasion des cellules B16F10.
About Me
PhD in vascular and cancer biology & PharmD student.
PhD in vascular and cancer biology & PharmD student.